|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7805 News |
|
| «12...130131132133134135136137138139140...156157» |
- | Trial completion, Enrollment change, FDG PET: Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma (clinicaltrials.gov) - Nov 26, 2012
P=N/A, N=77, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=100 --> 77 | Recruiting --> Completed
- New P1 trial: EDIA: Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity (clinicaltrials.gov) - Nov 26, 2012
P1, N=120, Recruiting, Sponsor: Helsinki University
- Trial completion: MIP: Nutritional Prevention Pilot Trial for Type 1 Diabetes (clinicaltrials.gov) - Nov 26, 2012
P2, N=230, Completed, Sponsor: Helsinki University
N=100 --> 77 | Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, FDG PET: Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma (clinicaltrials.gov) - Nov 26, 2012
P=N/A, N=77, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Completed
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P3 trial: Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Nov 25, 2012
P3, N=240, Recruiting, Sponsor: Shandong University
- || dexamethasone injection / Generic mfg.
New P3 trial: rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP (clinicaltrials.gov) - Nov 25, 2012
P3, N=200, Recruiting, Sponsor: Shandong University
- Enrollment closed: Efficacy of Methotrexate in Myasthenia Gravis (clinicaltrials.gov) - Nov 20, 2012
P2, N=50, Active, not recruiting, Sponsor: University of Kansas
Recruiting --> Completed Recruiting --> Active, not recruiting
- || Rituxan (rituximab) / Roche
New P3 trial: MAINRITSAN 2: Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis (clinicaltrials.gov) - Nov 20, 2012
P3, N=166, Active, not recruiting, Sponsor: Assistance Publique - H
- Enrollment change: Lido Workset Study (clinicaltrials.gov) - Nov 19, 2012
P=N/A, N=31, Completed, Sponsor: Mark Agius, MD
Recruiting --> Active, not recruiting N=75 --> 31
- || doxycycline / Generic mfg.
New P2/3 trial: Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients (clinicaltrials.gov) - Nov 19, 2012
P2/3, N=100, Completed, Sponsor: Federal University of São Paulo
- Trial completion: Agility LP Ankle Arthroplasty Outcomes (clinicaltrials.gov) - Nov 19, 2012
P=N/A, N=50, Completed, Sponsor: Orthopaedic Associates of Michigan, PC
N=75 --> 31 Active, not recruiting --> Completed
- Trial completion: Lido Workset Study (clinicaltrials.gov) - Nov 19, 2012
P=N/A, N=31, Completed, Sponsor: Mark Agius, MD
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Doptelet (avatrombopag) / SOBI
Trial initiation date: Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) (clinicaltrials.gov) - Nov 19, 2012
P3, N=49, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Initiation date: Dec 2011 --> Mar 2012
- Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
Trial initiation date: A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) (clinicaltrials.gov) - Nov 19, 2012
P3, N=24, Terminated, Sponsor: Eisai Inc.
Initiation date: Dec 2011 --> Mar 2012 Initiation date: Dec 2011 --> Apr 2012
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
New P3 trial: A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926 (clinicaltrials.gov) - Nov 19, 2012
P3, N=13, Active, not recruiting, Sponsor: Hoffmann-La Roche
- ||| Awiqli (insulin icodec) / Novo Nordisk
New P1 trial: A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Nov 19, 2012
P1, N=70, Completed, Sponsor: Novo Nordisk
- | New P2 trial: CISAVID: Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome (clinicaltrials.gov) - Nov 18, 2012
P2, N=84, Recruiting, Sponsor: University College Dublin
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Biomarker, Enrollment closed: Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis (clinicaltrials.gov) - Nov 18, 2012
P3, N=316, Active, not recruiting, Sponsor: Astellas Pharma Inc
Initiation date: Dec 2011 --> Apr 2012 Recruiting --> Active, not recruiting
- Trial termination: Assessing Continuous Non- Invasive Blood Glucose Sensor- Physical Logic AG (clinicaltrials.gov) - Nov 17, 2012
P=N/A, N=4, Terminated, Sponsor: Rabin Medical Center
Recruiting --> Active, not recruiting Suspended --> Terminated; sponsor decision
- Enrollment change: Assessing Continuous Non- Invasive Blood Glucose Sensor- Physical Logic AG (clinicaltrials.gov) - Nov 17, 2012
P=N/A, N=4, Terminated, Sponsor: Rabin Medical Center
Suspended --> Terminated; sponsor decision N=10 --> 4
- Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change, Combination therapy: A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 14, 2012
P4, N=2, Completed, Sponsor: Hoffmann-La Roche
N=10 --> 4 N=160 --> 2
- Clinical: Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics (clinicaltrials.gov) - Nov 14, 2012
P=N/A, N=75, Recruiting, Sponsor: Stanford University
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
New P3 trial: An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study (clinicaltrials.gov) - Nov 14, 2012
P3, N=11, Active, not recruiting, Sponsor: Hoffmann-La Roche
- doxycycline / Generic mfg.
New P1/2 trial: Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy (clinicaltrials.gov) - Nov 14, 2012
P1/2, N=14, Completed, Sponsor: Sun Yat-sen University
- | Promacta (eltrombopag) / Novartis
Enrollment closed: Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Nov 13, 2012
P2, N=12, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
N=160 --> 2 Recruiting --> Active, not recruiting
- |||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: SIERRA: A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate (clinicaltrials.gov) - Nov 13, 2012
P2, N=103, Completed, Sponsor: Genentech
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Rebif (human IFN-?-1a) / EMD Serono
Trial completion, Combination therapy: Combination Therapy Using Cellcept and Rebif in RRMS (clinicaltrials.gov) - Nov 13, 2012
P0, N=31, Completed, Sponsor: Aaron Boster
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Raptiva (efalizumab) / Roche, EMD Serono, Xoma
Enrollment change: Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes (clinicaltrials.gov) - Nov 12, 2012
P1/2, N=3, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed N=10 --> 3
- ||||| insulin peglispro (LY2605541) / Eli Lilly
Enrollment closed: A Study in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Nov 12, 2012
P3, N=450, Active, not recruiting, Sponsor: Eli Lilly and Company
N=10 --> 3 Recruiting --> Active, not recruiting
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Raptiva (efalizumab) / Roche, EMD Serono, Xoma
Trial completion: Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes (clinicaltrials.gov) - Nov 12, 2012
P1/2, N=3, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: FaBA: Improvement of a Physically Active Lifestyle (clinicaltrials.gov) - Nov 11, 2012
P=N/A, N=1377, Completed, Sponsor: Freie Universit
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open, MRI: Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study (clinicaltrials.gov) - Nov 10, 2012
P4, N=20, Recruiting, Sponsor: Singapore General Hospital
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Tysabri (natalizumab) / Biogen, Royalty
Trial termination, MRI: Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri (clinicaltrials.gov) - Nov 8, 2012
P4, N=8, Terminated, Sponsor: University Hospital, Strasbourg, France
Active, not recruiting --> Recruiting Completed --> Terminated
- ||||| aminopterin / Syntrix
New P2 trial: Aminopterin Dose Finding Treatment for Methotrexate-Naïve Rheumatoid Arthritis (clinicaltrials.gov) - Nov 8, 2012
P2, N=192, Recruiting, Sponsor: Syntrix Biosystems, Inc.
- Enrollment open: Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients (clinicaltrials.gov) - Nov 8, 2012
P2, N=50, Recruiting, Sponsor: Health Sciences Centre, Winnipeg, Manitoba
Completed --> Terminated Not yet recruiting --> Recruiting
- Trial initiation date: IPvsSC: Intraperitoneal vs Subcutaneous Insulin Administration in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Nov 8, 2012
P=N/A, N=190, Completed, Sponsor: Medical Research Foundation, The Netherlands
Not yet recruiting --> Recruiting Initiation date: Aug 2012 --> Dec 2012
- | Tavalisse (fostamatinib) / Rigel
New P1 trial, Combination therapy: Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib (clinicaltrials.gov) - Nov 8, 2012
P1, N=42, Completed, Sponsor: AstraZeneca
- | LAPS-Insulin (HM12460A) / Hanmi
New P1 trial: A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A (clinicaltrials.gov) - Nov 8, 2012
P1, N=48, Active, not recruiting, Sponsor: Hanmi Pharmaceutical Company Limited
- Enrollment closed: inMotion: Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI (clinicaltrials.gov) - Nov 7, 2012
P=N/A, N=108, Active, not recruiting, Sponsor: University of Washington
Initiation date: Aug 2012 --> Dec 2012 Recruiting --> Active, not recruiting
- Enrollment closed: TakeCharge: Telephone Delivered Self-management Intervention for People With Multiple Sclerosis (MS) (clinicaltrials.gov) - Nov 7, 2012
P=N/A, N=120, Active, not recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion: RemiTRAC: Remicade Infusion Management Program (clinicaltrials.gov) - Nov 7, 2012
P4, N=1630, Completed, Sponsor: Janssen Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment open: To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET) (clinicaltrials.gov) - Nov 7, 2012
P3, N=522, Recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment closed, HEOR: The Effect of the Use of Computer Game- "My Diabetic Friend" in Children With Type 1 Diabetes (clinicaltrials.gov) - Nov 7, 2012
P=N/A, N=40, Active, not recruiting, Sponsor: Rabin Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- dexamethasone injection / Generic mfg.
Trial completion: Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients (clinicaltrials.gov) - Nov 7, 2012
P1, N=50, Completed, Sponsor: Xiao-Ming Mao
Not yet recruiting --> Active, not recruiting Recruiting --> Completed
- Clinical: TRAP-Myéline: Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis (clinicaltrials.gov) - Nov 6, 2012
P=N/A, N=100, Recruiting, Sponsor: Nantes University Hospital
- Trial initiation date: Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study (clinicaltrials.gov) - Nov 6, 2012
P2, N=49, Completed, Sponsor: In Home Closed Loop Study Group
Recruiting --> Completed Initiation date: Jul 2012 --> Nov 2012
- ||| Trial completion: Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations (clinicaltrials.gov) - Nov 6, 2012
P1, N=82, Completed, Sponsor: Novo Nordisk
Initiation date: Jul 2012 --> Nov 2012 Recruiting --> Completed
- Enrollment open: Douleur-PR: Pain Evaluation in Rheumatoid Arthritis (clinicaltrials.gov) - Nov 5, 2012
P=N/A, N=300, Recruiting, Sponsor: University Hospital, Limoges
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Cosentyx (secukinumab) / Novartis
Biomarker, Enrollment change: A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients (clinicaltrials.gov) - Nov 4, 2012
P2, N=500, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=100 --> 500
- ||||| teriflunomide / Generic mfg.
Enrollment change: TOPIC: Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (clinicaltrials.gov) - Nov 4, 2012
P3, N=618, Active, not recruiting, Sponsor: Sanofi
N=100 --> 500 N=780 --> 618